|
1
|
Mokini Z and Chiarelli F: The molecular
basis of diabetic microangiopathy. Pediatr Endocrinol Rev.
4:138–152. 2006.PubMed/NCBI
|
|
2
|
Whiting DR, Guariguata L, Weil C and Shaw
J: IDF diabetes atlas: Global estimates of the prevalence of
diabetes for 2011 and 2030. Diabetes Res Clin Pract. 94:311–321.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Schulze MB and Hu FB: Epidemiology of
diabetesHandbook of Epidemiology. 2nd. Ahrens W and Pigeot I:
Springer; New York: pp. 2429–2467. 2014, View Article : Google Scholar
|
|
4
|
Zhang P, Zhang X, Brown J, Vistisen D,
Sicree R, Shaw J and Nichols G: Global healthcare expenditure on
diabetes for 2010 and 2030. Diabetes Res Clin Pract. 87:293–301.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chan JC, Malik V, Jia W, Kadowaki T,
Yajnik CS, Yoon KH and Hu FB: Diabetes in Asia: Epidemiology, risk
factors and pathophysiology. JAMA. 301:2129–2140. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ramachandran A, Snehalatha C, Shetty AS
and Nanditha A: Trends in prevalence of diabetes in Asian
countries. World J Diabetes. 3:110–117. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Head J and Fuller JH: International
variations in mortality among diabetic patients: The WHO
multinational study of vascular disease in diabetics. Diabetologia.
33:477–481. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Fioretto P, Dodson PM, Ziegler D and
Rosenson RS: Residual microvascular risk in diabetes: Unmet needs
and future directions. Nat Rev Endocrinol. 6:19–25. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Shishtar E, Jovanovski E, Jenkins A and
Vuksan V: Effects of Korean white ginseng (Panax Ginseng C.A.
Meyer) on vascular and glycemic health in Type 2 diabetes: Results
of a randomized, double blind, placebo-controlled,
multiple-crossover, acute dose escalation trial. Clin Nutr Res.
3:89–97. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hong YJ, Kim N, Lee K, Hee Sonn C, Eun Lee
J, Tae Kim S, Ho Baeg I and Lee KM: Korean red ginseng (Panax
ginseng) ameliorates type 1 diabetes and restores immune cell
compartments. J Ethnopharmacol. 144:225–233. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Liu Z, Li W, Li X, Zhang M, Chen L, Zheng
YN, Sun GZ and Ruan CC: Antidiabetic effects of malonyl
ginsenosides from Panax ginseng on type 2 diabetic rats induced by
high-fat diet and streptozotocin. J Ethnopharmacol. 145:233–240.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sen S, Chen S, Wu Y, Feng B, Lui EK and
Chakrabarti S: Preventive effects of North American ginseng (Panax
quinquefolius) on diabetic retinopathy and cardiomyopathy.
Phytother Res. 27:290–298. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Mucalo I, Jovanovski E, Vuksan V, Božikov
V, Romić Z and Rahelić D: American ginseng extract (Panax
quinquefolius L.) is safe in long-term use in type 2 diabetic
patients. Evid Based Complement Alternat Med. 2014:9691682014.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Jia W, Gao W and Tang L: Antidiabetic
herbal drugs officially approved in China. Phytother Res.
17:1127–1134. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yuan HD, Kim JT, Kim SH and Chung SH:
Ginseng and diabetes: The evidences from in vitro, animal and human
studies. J Ginseng Res. 36:27–39. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Committee for the Update of the Guide for
the Care and Use of Laboratory Animals, . Guide for the Care and
Use of Laboratory Animals. 6th. National Institutes of Health;
1985
|
|
17
|
Vuksan V, Sung MK, Sievenpiper JL, Stavro
PM, Jenkins AL, Di Buono M, Lee KS, Leiter LA, Nam KY, Arnason JT,
et al: Korean red ginseng (Panax ginseng) improves glucose and
insulin regulation in well-controlled, type 2 diabetes: Results of
a randomized, double-blind, placebo-controlled study of efficacy
and safety. Nutr Metab Cardiovasc Dis. 18:46–56. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Baecher-Allan C and Hafler DA: Human
regulatory T cells and their role in autoimmune disease. Immunol
Rev. 212:203–216. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Bingley PJ, Bonifacio E and Gale EA: Can
we really predict IDDM? Diabetes. 42:213–220. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
van den Oever IA, Raterman HG, Nurmohamed
MT and Simsek S: Endothelial dysfunction, inflammation, and
apoptosis in diabetes mellitus. Mediators Inflamm. 2010:7923932010.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Li Y, Chen M, Xuan H and Hu F: Effects of
encapsulated propolis on blood glycemic control, lipid metabolism,
and insulin resistance in type 2 diabetes mellitus rats. Evid Based
Complement Alternat Med. 2012:9818962012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Haller H, Drab M and Luft FC: The role of
hyperglycemia and hyperinsulinemia in the pathogenesis of diabetic
angiopathy. Clin Nephrol. 46:246–255. 1996.PubMed/NCBI
|
|
23
|
Hammes HP: Pathophysiological mechanisms
of diabetic angiopathy. J Diabetes Complications. 17:16–9. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kreisberg RA: Diabetic dyslipidemia. Am J
Cardiol. 82:67U–73U; discussion 85U-86U. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Warren RE: The stepwise approach to the
management of type 2 diabetes. Diabetes Res Clin Pract. 65:(Suppl
1). S3–S8. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
The Diabetes Control and Complications
Trial Research Group, . The effect of intensive treatment of
diabetes on the development and progression of long-term
complications in insulin-dependent diabetes mellitus. The diabetes
control and complications trial research group. N Engl J Med.
329:977–986. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
McGarry JD: Banting lecture 2001:
Dysregulation of fatty acid metabolism in the etiology of type 2
diabetes. Diabetes. 51:7–18. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Skrha J: Pathogenesis of angiopathy in
diabetes. Acta Diabetol. 40:(Suppl 2). S324–S329. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Bardini G, Rotella CM and Giannini S:
Dyslipidemia and diabetes: Reciprocal impact of impaired lipid
metabolism and Beta-cell dysfunction on micro- and macrovascular
complications. Rev Diabet Stud. 9:82–93. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Tilly-Kiesi M, Syvänne M, Kuusi T,
Lahdenperä S and Taskinen MR: Abnormalities of low density
lipoproteins in normolipidemic type II diabetic and nondiabetic
patients with coronary artery disease. J Lipid Res. 33:333–342.
1992.PubMed/NCBI
|
|
31
|
Stewart MW, Laker MF, Dyer RG, Game F,
Mitcheson J, Winocour PH and Alberti KG: Lipoprotein compositional
abnormalities and insulin resistance in type II diabetic patients
with mild hyperlipidemia. Arterioscler Thromb. 13:1046–1052. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Schalkwijk CG and Stehouwer CD: Vascular
complications in diabetes mellitus: The role of endothelial
dysfunction. Clin Sci (Lond). 109:143–159. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
De Caterina R: Endothelial dysfunctions:
Common denominators in vascular disease. Curr Opin Clin Nutr Metab
Care. 3:453–467. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Gupta K, Kshirsagar S, Li W, Gui L,
Ramakrishnan S, Gupta P, Law PY and Hebbel RP: VEGF prevents
apoptosis of human microvascular endothelial cells via opposing
effects on MAPK/ERK and SAPK/JNK signaling. Exp Cell Res.
247:495–504. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Pernow J, Shemyakin A and Böhm F: New
perspectives on endothelin-1 in atherosclerosis and diabetes
mellitus. Life Sci. 91:507–516. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Vlassara H, Cai W, Crandall J, Goldberg T,
Oberstein R, Dardaine V, Peppa M and Rayfield EJ: Inflammatory
mediators are induced by dietary glycotoxins, a major risk factor
for diabetic angiopathy. Proc Natl Acad Sci USA. 99:15596–15601.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Nakata H, Kikuchi Y, Tode T, Hirata J,
Kita T, Ishii K, Kudoh K, Nagata I and Shinomiya N: Inhibitory
effects of ginsenoside Rh2 on tumor growth in nude mice bearing
human ovarian cancer cells. Jpn J Cancer Res. 89:733–740. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Zhou W, Chai H, Lin PH, Lumsden AB, Yao Q
and Chen CJ: Molecular mechanisms and clinical applications of
ginseng root for cardiovascular disease. Med Sci Monit.
10:RA187–RA192. 2004.PubMed/NCBI
|
|
39
|
Xie JT, Mehendale SR, Li X, Quigg R, Wang
X, Wang CZ, Wu JA, Aung HH, A Rue P, et al: Anti-diabetic effect of
ginsenoside Re in ob/ob mice. Biochim Biophys Acta. 1740:319–325.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Han KL, Jung MH, Sohn JH and Hwang JK:
Ginsenoside 20S-protopanaxatriol (PPT) activates peroxisome
proliferator-activated receptor gamma (PPARgamma) in 3T3-L1
adipocytes. Biol Pharm Bull. 29:110–113. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Xie JT, Wang CZ, Wang AB, Wu J, Basila D
and Yuan CS: Antihyperglycemic effects of total ginsenosides from
leaves and stem of Panax ginseng. Acta Pharmacol Sin. 26:1104–1110.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Attele AS, Zhou YP, Xie JT, Wu JA, Zhang
L, Dey L, Pugh W, Rue PA, Polonsky KS and Yuan CS: Antidiabetic
effects of Panax ginseng berry extract and the identification of an
effective component. Diabetes. 51:1851–1858. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Cho WC, Chung WS, Lee SK, Leung AW, Cheng
CH and Yue KK: Ginsenoside Re of Panax ginseng possesses
significant antioxidant and antihyperlipidemic efficacies in
streptozotocin-induced diabetic rats. Eur J Pharmacol. 550:173–179.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Park EK, Choo MK, Han MJ and Kim DH:
Ginsenoside Rh1 possesses antiallergic and anti-inflammatory
activities. Int Arch Allergy Immunol. 133:113–120. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Zhang Z, Li X, Lv W, Yang Y, Gao H, Yang
J, Shen Y and Ning G: Ginsenoside Re reduces insulin resistance
through inhibition of c-Jun NH2-terminal kinase and nuclear
factor-kappaB. Mol Endocrinol. 22:186–195. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Gao Y, Yang MF, Su YP, Jiang HM, You XJ,
Yang YJ and Zhang HL: Ginsenoside Re reduces insulin resistance
through activation of PPAR-γ pathway and inhibition of TNF-α
production. J Ethnopharmacol. 147:509–516. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Uzayisenga R, Ayeka PA and Wang Y:
Anti-diabetic potential of Panax notoginseng saponins (PNS): a
review. Phytother Res. 28:510–516. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Quan HY, Yuan HD, Jung MS, Ko SK, Park YG
and Chung SH: Ginsenoside Re lowers blood glucose and lipid levels
via activation of AMP-activated protein kinase in HepG2 cells and
high-fat diet fed mice. Int J Mol Med. 29:73–80. 2012.PubMed/NCBI
|
